Company Overview - SI-BONE, Inc. (NASDAQ:SIBN) specializes in developing and selling medical devices aimed at treating musculoskeletal disorders in the sacropelvic area, including minimally invasive implants for sacroiliac joint dysfunction, pelvic trauma, and spinal support [3]. Stock Performance - The stock has experienced a decline of approximately 30% since January, raising concerns about its financial performance [1]. - Jim Cramer expressed skepticism regarding the stock's potential, indicating that the company is losing too much money and that the current market environment is challenging for money-losing stocks [1]. Investment Sentiment - Cramer acknowledged the speculative nature of SI-BONE, describing it as a "great, great speculation" and indicated a willingness to further investigate the company due to its frequent mention in discussions [3]. - Despite recognizing the potential of SI-BONE as an investment, there is a belief that certain AI stocks present greater upside potential with less downside risk [4].

Summary of SI-BONE FY Conference Call (March 02, 2026) Company Overview - **Company**: SI-BONE (NasdaqGM:SIBN) - **Industry**: MedTech, specifically focused on orthopedic solutions for SI joint dysfunction and related conditions Key Points and Arguments Company Evolution and Product Portfolio - SI-BONE has transitioned from a single product company focused on SI joint dysfunction to a diversified portfolio addressing multiple disease states related to compromised bone [3][5] - The company has developed technologies such as Granite for deformity and TNT for trauma, expanding its offerings beyond the original Triangle product [6][10] Market Strategy and Growth - The company aims to leverage its biomechanical engineering expertise to target markets with unmet needs and high failure rates in existing treatments [6][7] - SI-BONE has achieved a compound annual growth rate (CAGR) of about 20% since its IPO, significantly outperforming the overall orthopedic market growth [31][32] - The trauma market represents a $300 million total addressable market (TAM), while the overall TAM for SI-BONE is $3.5 billion [15][16] Partnership with Smith & Nephew - The partnership with Smith & Nephew is expected to enhance SI-BONE's reach in trauma surgery, allowing access to a larger segment of trauma surgeons [15][18] - This collaboration is designed to free up SI-BONE's sales representatives to focus on larger TAMs in spine and interventional markets [15][22] Product Launches and Innovations - SI-BONE is set to launch several new products, including INTRA Ti, which is designed to improve workflow efficiency for interventionalists [38][45] - The company has a robust pipeline of innovations, including a third Breakthrough Device expected to be filed for 510(k) approval in Q3 2026 [50][51] Financial Guidance and Market Trends - The company anticipates a deceleration in top-line growth for 2026 compared to 2025, but cites significant tailwinds such as increased reimbursement rates and new product launches [34][35] - Reimbursement for the allograft product is expected to increase by 20%-30% due to new policies, which will positively impact revenue [36][37] Operational Focus - The new COO, Anshul Maheshwari, emphasizes growth, field efficiency, and operational improvements to maintain high gross margins (currently at 78%-79%) [40][41] - The company is focused on reducing administrative burdens on sales representatives to enhance productivity [40][41] Long-term Outlook - SI-BONE is positioned for sustained growth with a focus on addressing unmet needs in the orthopedic market, particularly in compromised bone conditions [58][59] - The company plans to launch new products regularly over the next five years, targeting high failure rate procedures to expand its market presence [57][60] Additional Important Insights - The company has seen record numbers of interventionalists and trauma doctors performing procedures, indicating strong market traction [32][33] - SI-BONE's strategy includes maintaining a capital-light model while focusing on differentiated technologies with high gross margins [60][62]

Financial Performance and Profitability - SI-BONE has incurred significant operating losses since inception and may continue to do so in the future, impacting its ability to achieve profitability[12] - The company has incurred significant operating losses since inception and may continue to do so in the future, impacting its ability to achieve or sustain profitability[12] - The company is highly dependent on revenue from sales of products focused on procedures to stabilize and fuse the sacroiliac joint, which could negatively affect its financial condition[12] - Prolonged inflation and supply chain disruptions could lead to delayed product launches, lost revenue, higher costs, and decreased profit margins[12] Market Demand and Sales Strategy - The company relies heavily on sales from products addressing sacropelvic anatomy, which may affect its financial condition if demand shifts[16] - The uncertainty in coverage and reimbursement environments may decrease demand for the company's products, adversely affecting its business[12] - The company anticipates that a significant portion of its revenues will come from new products and indications for use[16] - The company expects a significant portion of its revenues to derive from sales of similar products addressing the sacropelvic anatomy[16] - The company must maintain its network of sales representatives and third-party agents to generate anticipated sales, highlighting the importance of its sales strategy[15] Regulatory and Compliance Risks - Regulatory compliance is critical, as failure to meet requirements could negatively impact the company's operations[15] - The company is subject to extensive governmental regulation, and any non-compliance could lead to adverse business consequences[15] - The company faces risks related to compliance with extensive governmental regulations, which could negatively impact its business[15] Supply Chain and Operational Risks - SI-BONE is dependent on a limited number of third-party suppliers, and any disruption could materially affect its business operations[12] - The company relies on a limited number of third-party suppliers, some of which are single-source, which poses a risk to its business operations[12] Competitive Landscape - The company faces pricing pressure from competitors and healthcare provider consolidation, which may impact its ability to sell products at necessary prices[12] - The company is subject to pricing pressure from competitors and healthcare provider consolidation, which may impact its ability to sell products at necessary prices[12] Growth and Development Opportunities - The company is focused on expanding its market presence and developing new products to enhance revenue opportunities[16] - The company’s ability to develop and commercialize additional revenue opportunities, including new products, is critical for future growth[16] - SI-BONE's ability to attract and retain key personnel is essential for maintaining its sales and operational effectiveness[19]

Group 1 - Zurich Insurance Group has agreed to acquire ClearView Wealth for A$408.3 million (approximately $288.30 million) [1] - ClearView shareholders will receive a cash consideration of 65 Australian cents per share, representing a 21.5% premium to its last closing price [2]

Core Insights - The company achieved its first full year of positive Adjusted EBITDA, with a gross margin of 79% in Q4 and 79.6% for the full year, exceeding its 2025 guidance by approximately 200 basis points [1][7] Financial Performance - For the full year 2025, worldwide revenue reached $200.9 million, marking a 20.2% increase, with U.S. revenue growing by 20.6% to $191.1 million due to a 22% rise in procedure volume [2] - In Q4 2025, the company reported worldwide revenue of $56.3 million, a 15% year-over-year increase, with U.S. revenue at $53.5 million (up 13.9%) and international revenue growing 38.8% to $2.9 million [3][7] - The net loss narrowed to $1.6 million in Q4, compared to a $4.5 million loss in the prior year, and for the full year, the net loss decreased by 38.8% to $18.9 million [8] Operational Highlights - The company reported a significant increase in physician adoption, with a 22% rise in U.S. physicians using its technologies, totaling nearly 22,000 procedures in 2025 [5][11] - In Q4 alone, 1,640 physicians performed procedures using the company's solutions, marking an 18% growth compared to the previous year [12] - The company ended the year with 89 quota-carrying territory managers, achieving an annual revenue per territory of $2.1 million, an 18% increase year-over-year [13] Reimbursement and Product Developments - Management highlighted key reimbursement milestones, including a 17% increase in Medicare reimbursement for office-based lab SI joint fusion, bringing it to nearly $14,000 [6][15] - The company received FDA 510(k) clearance for INTRA Ti and initiated an alpha launch, with expectations for adoption to ramp up through 2026 [16] - iFuse TORQ TNT saw a 50% increase in physician adoption in Q4, with NTAP reimbursement potentially being up to 30% higher in eligible cases [17] Future Guidance - For 2026, the company guided worldwide revenue between $228.5 million and $232.5 million, implying a growth rate of 14% to 16% [19] - The expected gross margin for 2026 is approximately 78%, with operating expenses anticipated to grow due to investments in surgical capacity [20] Strategic Partnerships - The company formed a strategic partnership with Smith+Nephew to enhance its reach in pelvic trauma, particularly in level 1 and level 2 trauma centers [21]

Financial Data and Key Metrics Changes - The company achieved record annual worldwide revenue of nearly $201 million, marking over 20% growth year-over-year [5][21] - Fourth quarter worldwide revenue grew 15% to a record $56.3 million, with U.S. revenue at $53.5 million, representing 13.9% growth [20] - Positive Adjusted EBITDA of $5.1 million in the fourth quarter, a 176.2% improvement over the prior year, with a 9.1% Adjusted EBITDA margin [23][24] - Net loss narrowed to $1.6 million or $0.04 per diluted share in the fourth quarter, compared to a net loss of $4.5 million or $0.11 per diluted share last year [22] Business Line Data and Key Metrics Changes - The company reported a 22% increase in U.S. physicians using its technologies, with nearly 22,000 procedures performed in 2025 [6][20] - INTRA Ti was launched recently, expected to enhance procedural efficiency in SI joint fusion [9][10] - iFuse Bedrock Granite has been one of the fastest-growing platforms, significantly outpacing the overall deformity market growth rate [11] Market Data and Key Metrics Changes - International revenue in the fourth quarter was $2.9 million, growing 38.8%, driven by the reception of iFuse TORQ [20] - The company secured favorable reimbursement positions, including NTAP for iFuse TORQ TNT and TPT for iFuse Bedrock Granite, enhancing access and adoption [6][11] Company Strategy and Development Direction - The company aims to lead the market for patients with compromised bone, focusing on innovation and market development [8] - A strategic partnership with Smith+Nephew was announced to expand reach in the trauma market, allowing trauma surgeons access to breakthrough technologies [16][29] - The next five years are viewed as an innovation super cycle, with plans to launch unique technologies targeting new clinical adjacencies [7][55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth potential, supported by a robust pipeline of innovative products and expanding market opportunities [28] - The company expects worldwide revenue of $228.5 million to $232.5 million in 2026, implying year-over-year growth of 14%-16% [25][26] - Management highlighted the importance of allowing tailwinds to materialize before fully incorporating them into revenue expectations [52][83] Other Important Information - The company exited 2025 with $147.8 million in cash and equivalents, marking a significant improvement in cash consumption compared to the previous year [24] - The company plans to add 10 new territories in 2026 to capture market opportunities [16][66] Q&A Session Summary Question: On the Smith+Nephew partnership, how did it come about and its potential contribution? - Management expressed excitement about the partnership, highlighting its potential to expand access to trauma solutions and allow the sales force to focus on market development [29][30] Question: Regarding clinical data showing similar outcomes for IPM physicians, will this increase engagement? - Management noted the growing interest in interventional business and the launch of INTRA Ti, which aligns with interventional spine physicians' workflows [32][34] Question: Can you clarify the guidance for Adjusted EBITDA in 2026? - Management indicated that while they expect an increase in Adjusted EBITDA, it would be slightly below $20 million [44] Question: What is the expected impact of INTRA Ti on the ASC market? - Management highlighted that INTRA Ti is designed for the ASC market and is expected to drive additional sales due to its simplicity and reimbursement coverage [46][62] Question: Can you discuss the cadence of revenue and the expected tailwinds? - Management noted that they expect more tailwinds than ever before, with a strong physician base and improved reimbursement backdrop [52][53]

Financial Data and Key Metrics Changes - The company generated record annual worldwide revenue of nearly $201 million, marking over 20% growth year-over-year [5][20] - Fourth quarter worldwide revenue grew 15% to a record $56.3 million, with U.S. revenue at $53.5 million, representing 13.9% growth [20] - The company achieved its first full year of positive adjusted EBITDA with a 9% adjusted EBITDA margin in the fourth quarter [7][23] - Net loss narrowed to $1.6 million or $0.04 per diluted share in the fourth quarter, compared to a net loss of $4.5 million or $0.11 per diluted share last year [22] Business Line Data and Key Metrics Changes - The number of U.S. physicians using the company's technologies increased by 22% in 2025, with nearly 22,000 procedures performed [6][20] - The company launched the INTRA Ti product, expected to enhance procedural efficiency in SI joint fusion [9][10] - iFuse Bedrock Granite has been one of the fastest-growing platforms, significantly outpacing the overall deformity market growth rate [11] Market Data and Key Metrics Changes - International revenue in the fourth quarter was $2.9 million, growing 38.8%, driven by the reception of iFuse TORQ [20] - The company expects to commercialize TNT in international markets in late 2026, ahead of the previously planned launch in 2027 [21] Company Strategy and Development Direction - The company is focused on an innovation-led growth strategy, with plans for a series of new product launches targeting new clinical adjacencies [4][8] - The partnership with Smith+Nephew aims to expand access to trauma solutions and enhance market penetration [30][31] - The company is positioned to lead in the sacropelvic space, addressing unmet needs for patients with compromised bone [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the business, supported by a robust pipeline of innovative products and expanding market opportunities [28] - The company anticipates worldwide revenue of $228.5 million to $232.5 million in 2026, implying year-over-year growth of 14%-16% [25][26] - Management highlighted the importance of allowing tailwinds to materialize before fully incorporating them into revenue expectations [53] Other Important Information - The company ended 2025 with $147.8 million in cash and equivalents, marking a significant improvement in cash consumption compared to 2024 [24] - The company plans to add 10 new territories in 2026 to capture market opportunities [16][66] Q&A Session Summary Question: How did the Smith+Nephew partnership come about and its potential contribution? - Management expressed excitement about the partnership, highlighting its potential to expand access to trauma solutions and enhance productivity [30][31] Question: Will the clinical data showing similar outcomes for IPM physicians help create more engagement? - Management confirmed that the INTRA Ti product is designed to cater to interventional spine physicians, enhancing engagement and procedural efficiency [32][34] Question: Can you clarify the guidance for adjusted EBITDA in 2026? - Management indicated that while they expect an increase in adjusted EBITDA, it would be slightly below $20 million [44] Question: What is the expected impact of the INTRA Ti product on the ASC market? - Management noted that INTRA Ti is expected to drive growth in the ASC market, providing a non-allograft solution that aligns with interventional spine physicians' workflows [46][62] Question: What are the drivers behind the gross margin guidance of 78%? - Management explained that the guidance reflects a mix of factors, including product launches and operational initiatives aimed at maintaining profitability [74][76]

Financial Data and Key Metrics Changes - The company generated record annual worldwide revenue of nearly $201 million, marking over 20% growth year-over-year [5][20] - Fourth quarter worldwide revenue grew 15% to a record $56.3 million, with U.S. revenue at $53.5 million, representing 13.9% growth [19][20] - The company achieved its first full year of positive Adjusted EBITDA, with a margin of 9% in the fourth quarter [6][23] - Net loss narrowed to $1.6 million or $0.04 per diluted share in the fourth quarter, compared to a net loss of $4.5 million or $0.11 per diluted share last year [22][23] - The company exited 2025 with $147.8 million in cash and equivalents, an increase of $2.1 million from the third quarter [24] Business Line Data and Key Metrics Changes - The U.S. physician base grew by 22%, with over 2,400 physicians performing nearly 22,000 procedures in 2025 [5][20] - The company launched the INTRA Ti product, which is expected to enhance procedural efficiency in ambulatory surgery centers [9][10] - iFuse Bedrock Granite has been one of the fastest-growing platforms, significantly outpacing the overall deformity market growth rate [11] Market Data and Key Metrics Changes - International revenue in the fourth quarter was $2.9 million, growing 38.8%, driven by the reception of iFuse TORQ [19][20] - The company secured favorable reimbursement positions, including NTAP for iFuse TORQ TNT and TPT for iFuse Bedrock Granite, enhancing access and adoption [5][11] Company Strategy and Development Direction - The company aims to lead the sacroiliac joint fusion market and expand into new clinical adjacencies, targeting unmet needs for patients with compromised bone [6][8] - The partnership with Smith+Nephew is expected to enhance market penetration in trauma solutions [16][30] - The company anticipates an innovation super cycle over the next five years, with regular product launches targeting new clinical adjacencies [7][57] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the business, supported by a robust pipeline of innovative products and expanding market opportunities [27] - The company expects worldwide revenue of $228.5 million to $232.5 million in 2026, implying year-over-year growth of 14%-16% [25][26] - Management highlighted the importance of allowing tailwinds to materialize before fully incorporating them into revenue expectations [54][86] Other Important Information - The company achieved positive free cash flow in the fourth quarter, generating nearly $500,000, ahead of its previously stated goal [24] - The company plans to add 10 new territories in 2026 to capture market opportunities [16][69] Q&A Session Summary Question: How did the Smith+Nephew partnership come about and its potential contribution? - Management expressed excitement about the partnership, highlighting its potential to expand access to trauma solutions and allow the sales force to focus on spine and interventional markets [30][32] Question: Will the INTRA Ti product create more engagement among interventional physicians? - Management confirmed that the INTRA Ti product is designed to improve procedural efficiency and is expected to drive growth in the interventional business [34][49] Question: What is the rationale behind the high teens growth guidance for 2026? - Management explained that the guidance considers the impact of new products and reimbursement coverage, with a focus on prudent expectations early in the year [86] Question: What is the expected ramp-up for the Smith+Nephew partnership in 2026? - Management indicated that activity is expected to start in March, with a ramp-up in Q2 and Q3 in preparation for Q4 [74][75]

SI-BONE Corporate Overview Recent Highlights – Record Performance Fourth Quarter 2025 Fiscal Year 2025 Note: Financial As of February 18, 2026 February 2026 Forward-Looking Statements The statements in this presentation regarding expectations of future events or results, including SI-BONE's expectations of continued revenue and procedure growth and financial outlook, are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve signific ...

Core Insights - SI-BONE, Inc. achieved a 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025, indicating strong business performance and operational efficiency [1][4][10] - The company generated free cash flow in the Fourth Quarter of 2025, reflecting improved financial health [1][7] Financial Highlights - Fourth Quarter 2025 worldwide revenue was $56.3 million, a 15.0% increase from $49.0 million in the same period of 2024 [5][7] - U.S. revenue for the fourth quarter was $53.5 million, up 13.9% from $46.9 million in the prior year [5][7] - International revenue for the fourth quarter reached $2.9 million, a significant increase of 38.8% from $2.1 million in the previous year [5][7] - Gross profit for the fourth quarter was $44.5 million, a 14.8% increase from $38.8 million in the corresponding period in 2024, with a stable gross margin of 79.0% [6][7] Annual Performance - For Fiscal Year 2025, worldwide revenue totaled $200.9 million, representing a 20.2% increase from $167.2 million in 2024 [10][12] - U.S. revenue for the year was $191.1 million, a 20.6% increase from $158.4 million in 2024 [10][12] - International revenue was $9.8 million, a 12.4% increase from $8.8 million in the previous year [10] Profitability Metrics - The company reported a net loss of $1.6 million in the fourth quarter, an improvement of 63.3% compared to a net loss of $4.5 million in the same period in 2024 [9][12] - Adjusted EBITDA for the fourth quarter was positive at $5.1 million, representing a 176.2% improvement from $1.9 million in the prior year [9][12] - For the full year, the net loss improved by 38.8% to $18.9 million, or $0.44 per diluted share, compared to a net loss of $30.9 million, or $0.75 per diluted share in 2024 [12] Operational Developments - Approximately 1,640 U.S. physicians performed procedures using SI-BONE's products in the fourth quarter, marking an 18% increase [7] - The company entered into a strategic partnership with Smith+Nephew to distribute its products across trauma centers nationwide [7] - SI-BONE expanded its INTRA platform with the launch of INTRA Ti, enhancing procedural flexibility for physicians [7] Future Outlook - For 2026, SI-BONE expects worldwide revenue to be between $228.5 million and $232.5 million, indicating a year-over-year growth of approximately 14% to 16% [13] - The company anticipates a gross margin of around 78% and operating expenses growth of approximately 12.5% at the midpoint of the revenue guidance [13]